160 related articles for article (PubMed ID: 22498722)
1. Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer.
Hanna N; Ohana P; Konikoff FM; Leichtmann G; Hubert A; Appelbaum L; Kopelman Y; Czerniak A; Hochberg A
Cancer Gene Ther; 2012 Jun; 19(6):374-81. PubMed ID: 22498722
[TBL] [Abstract][Full Text] [Related]
2. A phase 1/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian/peritoneal cancer.
Lavie O; Edelman D; Levy T; Fishman A; Hubert A; Segev Y; Raveh E; Gilon M; Hochberg A
Arch Gynecol Obstet; 2017 Mar; 295(3):751-761. PubMed ID: 28154921
[TBL] [Abstract][Full Text] [Related]
3. BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers.
Smaldone MC; Davies BJ
Curr Opin Mol Ther; 2010 Oct; 12(5):607-16. PubMed ID: 20886393
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin.
Sidi AA; Ohana P; Benjamin S; Shalev M; Ransom JH; Lamm D; Hochberg A; Leibovitch I
J Urol; 2008 Dec; 180(6):2379-83. PubMed ID: 18950807
[TBL] [Abstract][Full Text] [Related]
5. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.
Mulvihill S; Warren R; Venook A; Adler A; Randlev B; Heise C; Kirn D
Gene Ther; 2001 Feb; 8(4):308-15. PubMed ID: 11313805
[TBL] [Abstract][Full Text] [Related]
6. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.
Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M
Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382
[TBL] [Abstract][Full Text] [Related]
8. Adenocarcinoma of the pancreatic head: a community teaching hospital's experience from 1982 to 1992.
Falk J; Keidan R; Rigo PK; Dmuchowski C
Am Surg; 1999 Jan; 65(1):15-8. PubMed ID: 9915524
[TBL] [Abstract][Full Text] [Related]
9. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.
Hirooka Y; Kasuya H; Ishikawa T; Kawashima H; Ohno E; Villalobos IB; Naoe Y; Ichinose T; Koyama N; Tanaka M; Kodera Y; Goto H
BMC Cancer; 2018 May; 18(1):596. PubMed ID: 29801474
[TBL] [Abstract][Full Text] [Related]
10. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
Vestermark LW; Jensen HA; Pfeiffer P
Acta Oncol; 2012 Mar; 51(3):311-7. PubMed ID: 22248062
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation of concurrent hypofractionated radiotherapy and continuous infusion 5-FU-chemotherapy in advanced adenocarcinoma of the pancreas.
Zimmermann FB; Jeremic B; Lersch C; Geinitz H; Hennig M; Molls M
Hepatogastroenterology; 2005; 52(61):246-50. PubMed ID: 15783041
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of hyperfractionated accelerated chemoradiotherapy for unresectable advanced pancreatic cancer.
Tsujie M; Nakamori S; Tanaka E; Nagano H; Umeshita K; Dono K; Sakon M; Inoue T; Inoue T; Monden M
Jpn J Clin Oncol; 2006 Aug; 36(8):504-10. PubMed ID: 16855011
[TBL] [Abstract][Full Text] [Related]
13. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
[TBL] [Abstract][Full Text] [Related]
14. Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study.
Sasada T; Denno R; Tanaka T; Kanai M; Mizukami Y; Kohno S; Takabayashi A
Am J Clin Oncol; 2008 Feb; 31(1):71-8. PubMed ID: 18376231
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced non-small cell lung cancer.
Li BS; Gong HY; Huang W; Yi Y; Yu JM; Wang ZT; Zhang ZC; Sun HF; Li HS; Wang LY
Am J Clin Oncol; 2012 Apr; 35(2):115-9. PubMed ID: 21555933
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
Ganly I; Kirn D; Eckhardt G; Rodriguez GI; Soutar DS; Otto R; Robertson AG; Park O; Gulley ML; Heise C; Von Hoff DD; Kaye SB
Clin Cancer Res; 2000 Mar; 6(3):798-806. PubMed ID: 10741699
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
18. Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma.
Furuse J; Kinoshita T; Kawashima M; Ishii H; Nagase M; Konishi M; Nakagohri T; Inoue K; Ogino T; Ikeda H; Maru Y; Yoshino M
Cancer; 2003 Mar; 97(5):1346-52. PubMed ID: 12599244
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction.
Safran H; Akerman P; Cioffi W; Gaissert H; Joseph P; King T; Hesketh PJ; Wanebo H
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):53-7. PubMed ID: 10210540
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
Dittrich C; Dumez H; Calvert H; Hanauske A; Faber M; Wanders J; Yule M; Ravic M; Fumoleau P
Clin Cancer Res; 2003 Nov; 9(14):5195-204. PubMed ID: 14613999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
